C

Compugen Ltd
D

CGEN

1.45000
USD
0.02
(1.40%)
Market Closed
Volume
0
EPS
-1
Div Yield
-
P/E
-15
Market Cap
129,827,826
Related Instruments
    AMGN
    AMGN
    -12.22
    (-4.13%)
    289.88 USD
    BMY
    BMY
    -2.270
    (-3.88%)
    56.230 USD
    GILD
    GILD
    -3.715
    (-4.03%)
    88.385 USD
    I
    INCY
    -1.840
    (-2.37%)
    75.890 USD
    MRNA
    MRNA
    -2.950
    (-7.42%)
    36.830 USD
    NVS
    NVS
    -0.350
    (-0.34%)
    103.85 USD
    REGN
    REGN
    -25.40
    (-3.25%)
    756.82 USD
    More
News

Title: Compugen Ltd

Sector: Healthcare
Industry: Biotechnology
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902, bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.